Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8911731
SERIAL NO

14233068

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides monoclonal antibodies which specifically recognize the shorter Aβ peptides obtained after cleavage of the APP protein mediated by γ-secretase, i.e. the Aβ-peptide fragments Aβ1-37, Aβ3-37, Aβ3p-37, Aβ1-37 and Aβ11p-37, and other like fragments ending at the 37th amino acid of APP, hereinafter also referred to as the Aβx-37 peptides. It further provides hybridoma cells producing the monoclonal antibodies as well as methods for producing the antibodies and the hybridoma cells; and an immunoassay for an Aβx-37 peptide by a competitive method or a sandwich method using the antibody of the present invention; and methods for measuring the level of Aβx-37 peptides in a sample, such as a biological sample.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • JANSSEN PHARMACEUTICA NV

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Borgers, Marianne Balen, BE 5 5
Mercken, Marc Hubert Beerse, BE 8 73
Van, Broeck Bianca Julia J Beerse, BE 1 1
Vandermeeren, Marc Maria Pierre Pelagie Beerse, BE 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 16, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00